Anti-BCMA CAR T-Cell Therapy for R/R ITP

Inclusion Criteria: * Refractory ITP defined according to the recent consensual criteria ( 'Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)'), or relapse ITP defined as ITP patients who have responded to first-line therapy (glucocorticoids or immunoglobulins) and anti-CD20 monoclonal antibody, but cannot maintain the response. * Ages 18-65 years inclusive. * Adequate venous access for apheresis or venous blood and no other contraindications for leukocytosis. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Subjects should have full capacity for civil conduct, understand necessary information，sign the informed consent form voluntarily，and have good corporation with the content of this research protocol. Exclusion Criteria: * Secondary ITP. * Patients with a known history or prior diagnosis of arterial thrombosis (such as cerebral thrombosis, myocardial infarction, etc.), or comorbidity of venous thrombosis (such as deep vein thrombosis, pulmonary embolism), or are using anticoagulant/antiplatelet drug at the beginning of trial. * Patients with a known history or prior diagnosis of serious cardiovascular disease. * Patients with uncontrolled infection, organ dysfunction or any uncontrolled active medical disorder that would preclude participation as outlined. * Patients with malignancy or history of malignancy. * Failed T cell expansion test. * During screening, hemoglobin \<100g/L; absolute va…